Intratumoral and Peritumoral Radiomics Based on Preoperative MRI for Evaluation of Programmed Cell Death Ligand‐1 Expression in Breast Cancer
Journal of Magnetic Resonance Imaging · 2024
DOI: 10.1002/jmri.29109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Magnetic Resonance Imaging, 2024. Verfasst von Zengjie Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Magnetic Resonance Imaging, B7-H1 Antigen, Contrast Media. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
Programmed cell death ligand‐1 (PD‐L1) is a promising target for immune checkpoint blockade therapy in breast cancer. However, the preoperative evaluation of PD‐L1 expression in breast cancer is rarely explored.
Purpose
To determine the ability of radiomics signatures based on preoperative dynamic contrast‐enhanced (DCE) MRI to evaluate PD‐L1 expression in breast cancer. Study Type Retrospective. Population 196 primary breast cancer patients with preoperative MRI and postoperative pathological evaluation of PD‐L1 expression, divided into training ( n = 137, 28 PD‐L1‐positive) and test cohorts ( n = 59, 12 PD‐L1‐positive). Field Strength/Sequence 3.0T; volume imaging for breast assessment DCE sequence. Assessment Radiomics features were extracted from the first phase of DCE‐MRI by using the minimum redundancy maximum relevance method and least absolute shrinkage and selection operator algorithm. Three radiomics signatures were constructed based on the intratumoral, peritumoral, and combined intra‐ and peritumoral regions. The performance of the signatures was assessed using area under the receiver operating characteristic (ROC) curve (AUC), sensitivity, specificity, and accuracy. Statistical Tests Univariable and multivariable logistic regression analysis, t ‐tests, chi‐square tests, Fisher exact test or Yates correction, ROC analysis, and one‐way analysis of variance. P < 0.05 was considered significant.
Results
In the test cohort, the combined radiomics signature (AUC, 0.853) exhibited superior performance compared to the intratumoral (AUC, 0.816; P = 0.528) and peritumoral radiomics signatures (AUC, 0.846; P = 0.905) in PD‐L1 status evaluation, although the differences did not reach statistical significance. Data Conclusion Intratumoral and peritumoral radiomics signatures based on preoperative breast MRI showed some potential accuracy for the non‐invasive evaluation of PD‐L1 status in breast cancer. Level of Evidence 4 Technical Efficacy Stage 2
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
- Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
- Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
ORCID-Profile: Tiantian Bian
Zitieren
APA
Wu, Z., Lin, Q., Wang, H., Chen, J., Wang, G., Fu, G., Li, L., & Bian, T. (2024). Intratumoral and Peritumoral Radiomics Based on Preoperative MRI for Evaluation of Programmed Cell Death Ligand‐1 Expression in Breast Cancer. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.29109
Vancouver
Wu Z, Lin Q, Wang H, Chen J, Wang G, Fu G, et al. Intratumoral and Peritumoral Radiomics Based on Preoperative MRI for Evaluation of Programmed Cell Death Ligand‐1 Expression in Breast Cancer. Journal of Magnetic Resonance Imaging. 2024. doi:10.1002/jmri.29109
BibTeX
@article{Wu2024,
author = {Wu, Zengjie and Lin, Qing and Wang, Haibo and Chen, Jingjing and Wang, Guanqun and Fu, Guangming and Li, Lili and Bian, Tiantian},
title = {Intratumoral and Peritumoral Radiomics Based on Preoperative MRI for Evaluation of Programmed Cell Death Ligand‐1 Expression in Breast Cancer},
journal = {Journal of Magnetic Resonance Imaging},
year = {2024},
doi = {10.1002/jmri.29109}
}
EUVIMED